If My Prostate Cancer Is PSMA-Positive and Hormone-Sensitive, Can I Get Lu-177 PSMA Therapy Before It Becomes Castration-Resistant — and What Does the Evidence Say About Early Access?

Two Ways Prostate Cancer Can Behave — and Why It Matters

Prostate cancer grows because of testosterone. In early advanced disease, doctors use hormone therapy (also called androgen deprivation therapy, or ADT) to lower testosterone. When a man on this therapy finds his cancer still responds, he has hormone-sensitive prostate cancer. Some doctors call it castration-sensitive disease. Once the cancer grows despite very low testosterone, it becomes castration-resistant prostate cancer, or mCRPC. The National Cancer Institute explains that most prostate cancers eventually stop responding to hormone therapy and keep growing even when androgen levels stay very low. This difference in disease stage determines who qualifies for Lu-177 PSMA therapy.

What the FDA Has Approved — and for Which Stage

As of mid-2026, the FDA approves Lu-177 PSMA therapy only for men with castration-resistant prostate cancer. The approval has grown over time but doesn't yet cover hormone-sensitive disease. Here's how the approved label has expanded:

• March 2022: The FDA first approved Lu-177 PSMA-617 for men with mCRPC who had already received both an androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy. The VISION trial led to this approval.
• March 2025: The FDA expanded the approval to include taxane-naive men with mCRPC who had progressed on an ARPI and when delaying chemotherapy made sense. The PSMAfore phase 3 trial supported this decision, showing a 59% reduction in the risk of radiographic progression or death (HR 0.41) and more than doubling median radiographic progression-free survival compared to switching ARPI agents (11.6 months vs. 5.6 months).

The Prostate Cancer Foundation noted that this 2025 expansion nearly triples the number of mCRPC patients now eligible for treatment. In both approvals, castration-resistant is the key phrase. Hormone-sensitive disease is a separate stage and doesn't yet fall within the FDA-approved label for this therapy.

For a detailed look at the PSMAfore findings and what they mean for men who have not yet received chemotherapy, see the related article PSMAfore: Lu-177 PSMA Therapy Before Chemotherapy Shows Benefit.

Being PSMA-Positive Is Necessary — But Not Enough on Its Own

Having PSMA-positive tumors is necessary for Lu-177 PSMA therapy, but it's not the only requirement. PSMA stands for prostate-specific membrane antigen. It's a protein on the surface of most prostate cancer cells. A PSMA PET scan (usually using gallium-68 PSMA-11) shows where PSMA-expressing deposits are in the body. The National Cancer Institute describes how VISION trial patients had to have at least one lesion with tracer uptake visually greater than the liver. This became the standard for PSMA positivity. Even if your PSMA PET scan shows clear positivity, that alone won't qualify you for therapy today if your cancer still responds to hormone treatment. You must also have castration-resistant disease under the current label. If you have questions about mixed PSMA PET results and future eligibility, the article What Are My Real Chances of Qualifying for Lu-177 PSMA Therapy If My PSMA PET Scan Shows Mixed Results covers that topic fully.

What the Emerging Trial Evidence Shows

This is an active area of research. Several teams have studied whether Lu-177 PSMA therapy might help men earlier, before their cancer becomes castration-resistant. The findings so far are encouraging, though not yet strong enough for regulatory approval in most countries.

PSMAddition (Phase 3 Trial in Hormone-Sensitive Disease): PSMAddition is the largest study in hormone-sensitive disease so far. It enrolled over 1,100 men with PSMA-positive metastatic hormone-sensitive prostate cancer. Men received either standard of care alone (ADT plus an ARPI) or the same standard care with added Lu-177 PSMA-617. The trial met its primary goal, showing a statistically significant improvement in radiographic progression-free survival for men who received the radioligand therapy. Researchers presented results at major oncology meetings in 2025. Overall survival data showed a positive trend favoring the treatment group but didn't yet reach statistical significance at first reporting. This is common in trials where control-arm patients can later receive the experimental therapy, a crossover that makes it harder to spot an overall survival benefit. Follow-up is ongoing.

BULLSEYE and Pilot Studies in Oligometastatic Disease: Smaller investigator-led studies looked at Lu-177 PSMA therapy in men with oligometastatic hormone-sensitive prostate cancer (cancer spread to only a few sites). A pilot study update published in 2024 found the therapy was feasible and had manageable safety in low-volume hormone-sensitive disease. Men with a PSA drop greater than 50% seemed to benefit most, including a delay before starting long-term continuous hormone therapy. These were small, early-stage studies, so results are early signals rather than definitive proof.

High-Volume mHSPC Consolidation (Phase 2 Trial): A small randomized phase 2 trial tested Lu-177 PSMA-617 as a consolidation treatment after chemotherapy in men with high-volume metastatic hormone-sensitive disease. More men in the Lu-177 group than the control group met the primary goal, and radiographic progression-free survival was longer in the treated group. Again, this is a small dataset needing confirmation in larger trials.

Why There Is a Gap Between Trial Data and Regulatory Approval

The gap between promising trial results and formal approval can feel frustrating. But regulators like the FDA usually require large phase 3 trials showing clear benefit, ideally in overall survival, before approving a therapy for a new patient group. For hormone-sensitive disease, PSMAddition data show a meaningful improvement in radiographic progression-free survival, but overall survival results are still developing. Until those results finish and reviewers examine them, this therapy isn't recommended routinely in hormone-sensitive patients outside of clinical trials. This isn't unusual. ARPIs like enzalutamide and abiraterone took the same path: first approved for castration-resistant disease before later benefiting hormone-sensitive patients too.

Does Waiting Until Castration Resistance Put You at a Disadvantage?

Some men and caregivers wonder whether waiting means missing a window. Based on current evidence, this concern is understandable but not strongly supported for most patients. Several points matter:

• Hormone therapy, especially combined with a modern ARPI, can control metastatic prostate cancer for a long time before resistance develops. The time to castration resistance varies greatly between individuals.
• The PSMA protein stays highly expressed through the castration-resistant stage and often increases as disease advances. In most patients, PSMA expression doesn't disappear, so therapy remains a viable option when that stage arrives.
• The Prostate Cancer Foundation notes that the more PSMA expression a cancer has, the more the tumor is targeted by the radioligand therapy. Higher expression links to better response. This profile generally stays the same or increases through disease progression.
• With the 2025 expanded FDA approval, men with mCRPC now get access to Lu-177 PSMA therapy earlier, before chemotherapy, giving those who reach that stage more time with this option.

If your hormone therapy has already stopped working, the article My Prostate Cancer Stopped Responding to Hormone Therapy — What Are My Options Before Chemotherapy outlines available choices.

Understanding Where You Stand on the Treatment Pathway

Your oncology team will use various markers to track your disease stage over time. The move from hormone-sensitive to castration-resistant disease typically shows up as:

• A rising PSA level despite testosterone being suppressed to castrate levels (typically below 50 ng/dL)
• New or growing lesions appearing on imaging scans while on hormone therapy
• New or worsening symptoms suggesting disease progression

When these criteria happen, the mCRPC label typically applies, and that's when reviewing Lu-177 PSMA eligibility becomes appropriate. Having done a PSMA PET scan during the hormone-sensitive phase is valuable: it shows your disease, confirms PSMA expression, and means your team can act quickly once you meet eligibility criteria.

Can You Access Lu-177 PSMA Therapy in a Clinical Trial Right Now?

For men who are hormone-sensitive and want earlier access, a clinical trial may be the best route. Follow-on studies building on PSMAddition results are expected as the field grows. Your oncologist can search for available trials through ClinicalTrials.gov. In India and other countries with active lutetium therapy centers, some may offer clinical trial participation or compassionate use programs, though these vary and must be confirmed with your care team. Most trials still require PSMA-positive imaging and specific disease features your oncologist can assess.

When to Talk to Your Doctor

Bring these questions to your oncologist or a specialist in nuclear medicine or radioligand therapy if any of these apply:

• Your PSA is rising despite current hormone therapy and you want to know what it means for your disease stage.
• You had a PSMA PET scan and want to understand how results may affect future treatment options.
• You want to know whether clinical trials studying Lu-177 PSMA in hormone-sensitive disease are available at centers near you or internationally.
• You've reached or are approaching castration-resistant disease and want to check if you're eligible for Lu-177 PSMA therapy.
• You want a second opinion from a center with specific experience in radioligand therapy.

This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.